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“After all muscle moves the world” 
Sir Charles Sherrington 
  
  
  
ABSTRACT 
 
Skeletal muscle is an essential component of the human body, being one of the most dynamic 
and plastic tissues. As such it can be altered by numerous confounding factors. Critical illness 
myopathy is a common and complex manifestation seen in the intensive care unit and it has 
over the past decade become an increasing problem that will only escalate further with time. 
Understanding the processes and underlying mechanisms of muscle regulation with respect to 
critical illness myopathy is an area of great research focus and aims to improve scientific 
knowledge and patient care. My thesis has provided further insight into this highly 
orchestrated process. The overall goal of my PhD project was to investigate the importance of 
two potential contributors, nutrition and ageing, in the development of muscle fibre 
dysfunction in response to the intensive care unit condition; critical illness myopathy, and 
evaluate the efficiency of one potential therapeutic intervention (BGP-15) using a rodent 
model mimicking the intensive care unit environment.  
Nutritional feeding of a eucaloric vs low caloric diet was found not to differ in the 
preferential myosin loss, decline in specific force and muscle fibre atrophy of the limb 
muscles after a period of controlled mechanical ventilation of up to 14 days. The term 
“specific force” has been accepted as an indicator of muscle quality and is the generated force 
by a muscle adjusted for its size. In both experimental groups, passive mechanical loading 
had a sparing effect of muscle weight independent of nutritional status. We observed in both 
young and old rats an unexpected response of the diaphragm ﬁbres to 5 days controlled 
mechanical ventilation, an ineffective compensatory hypertrophy, in conjunction with a 
decreased maximum force in both age groups compared with controls, resulting in an age 
related dramatic loss of speciﬁc force. Administration of the pharmacological intervention 
BGP-15 demonstrated that after 10 days controlled mechanical ventilation the specific force 
of diaphragm muscle fibres increased by more than 100% compared to untreated muscle 
fibres. Furthermore when BGP-15 was administered to young and old rats, after 5 days 
controlled mechanical ventilation the age dependent significant drop in diaphragm fibre force 
production was restored, however only in the young. This concomitant increase in force in 
the young was observed also in the expression of heat shock protein 72. Thus, it is suggested 
that the increased Hsp72 expression, induced by BGP-15 is an indicator of the inhibition of 
the atrophy pathway (UPS) that as such attributes to an increased cross sectional area and 
specific force in only the young. 
It is of crucial importance to comprehend in more depth the effect of mechanical ventilation 
on limb and diaphragm function in the intensive care setting in order to ascertain any further 
age- related differences. We have determined here that BGP-15 is a possible intervention 
strategy that needs to be explored further to investigate the underlying mechanisms of action 
in order to implement the possible highly clinical significance of this research.  
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1 INTRODUCTION 
 
1.1 SKELETAL MUSCLE: STRUCTURE AND FUNCTION 
 
Skeletal muscle is the largest tissue in the human body, comprising about 40% of the body’s 
weight and is further considered an organ. It is one of the most dynamic and plastic tissues of 
the human body. The main function of skeletal muscle is to generate force and power, 
maintain the body’s posture and produce movement allowing us to perform everyday tasks 
and activities. More specifically from a mechanical point of view its function is to convert 
chemical energy into mechanical energy; from a metabolic perspective, the role of skeletal 
muscle includes a contribution to basal energy metabolism, serving as storage for important 
substrates such as amino acids and carbohydrates, the production of heat for the maintenance 
of core body temperature and the consumption of the majority of oxygen and fuel used during 
physical activity and exercise. As such skeletal muscle is a highly complex and orchestrated 
tissue.  
 
1.1.1 Muscle: from protein to movement 
1.1.1.1 Muscle Proteins 
 
Within skeletal muscle, each individual muscle fibre divides into thousands of myofibrils, 
which contains billions of myofilaments (see figure 1). The two most abundant myofilaments 
(proteins) are actin and myosin, with myosin being the molecular motor protein. It is the 
myofilaments when assembled together in a characteristic (cross-striated) pattern that form 
sarcomeres. Muscle contraction is achieved by shortening of the sarcomeres caused by the 
interaction between the contractile myosin and actin filaments, as described by the “sliding 
filament model” (Huxley and Niedergerke, 1954; Huxley and Hanson, 1954).  
It is the numerous proteins that contribute to the structure of the cytoskeleton, coupling of the 
excitation and contraction processes, energy release and the generation of force and power 
(Gordon et al., 2000), all of which play important and individual roles. Of particular 
importance are the regulatory proteins such as the calcium-dependent troponin complex and 
tropomyosin, which are associated with the actin filament and play very important roles in the 
activation process that leads to myofilament sliding and thus force generation. 
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Figure 1. Structure of skeletal muscle (Sherwood, 2010) 
 
1.1.2 Excitation–Contraction Coupling: Physiology of Muscle Activation  
 
In order for muscle to generate force, thus allowing us to move our bodies, a process must 
first occur, Excitation–contraction (EC) coupling. This is the coordination of two processes; 
the transmission of the nerve stimulus followed by the depolarization of the sarcolemma and 
the consequent release of calcium from the sarcoplasmic reticulum and the resultant 
interaction between the two proteins actin and myosin that form cross-bridges. Briefly, when 
an action potential arrives at the muscle fibre membrane and is conducted into the interior of 
the muscle cell via the transverse tubular (T tubule), a voltage-gated sensor on the T tubule 
opens, allowing a flow of calcium inwards causing the opening of the ryanodine receptors in 
the sarcoplasmic reticulum. This allows calcium to be released in large amounts into the 
sarcoplasm. The calcium released into the sarcoplasm then binds to the regulatory protein 
troponin C on the actin thin myofilament, causing troponin to change shape, which in turn 
initiates a series of molecular events. Tropomyosin moves away from the myosin binding 
sties on actin allowing the myosin head to bind actin and form a cross bridge. The detailed 
structure of the myosin head was described for the first time in 1993 (Rayment et al., 1993) 
and contributed significantly to our understanding of the mechanics and physiology of this 
process. As mentioned before, the end-result of this sequence of events is the sliding of the 
actin and myosin filaments and the generation of force. The force generated by individual 
actin–myosin cross-bridges is transmitted longitudinally and laterally within the fibre. 
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1.1.3 Generating Force and Movement  
 
The sliding filament theory (1954) (Huxley and Niedergerke, 1954; Huxley and Hanson, 
1954) explains the basic molecular mechanisms by which muscle fibres generate force via the 
cross bridge cycle (see figure 2).  
 
Figure 2. Cross bridge cycle. Actomyosin interaction during contraction. 
This cycle begins when adenosine triphosphate (ATP) is made available to an existing actin-
myosin cross bridge and binds to the myosin head resulting in the dissociation of myosin 
from actin and the detachment of the existing cross-bridge (see figure 2 [1]). ATP is 
hydrolysed to adenosine diphosphate (ADP) and inorganic phosphate (Pi), the energy 
generated activates the myosin head to be moved (see figure 2 [2]) and binds weakly to a new 
actin molecule, forming a new cross bridge (see figure 2 [3]). Release of Pi triggers a power 
stoke and myosin pushes the actin filament past it towards the centre of the sarcomere. Force 
is generated during this power stroke (see figure 2 [4]). At the end of the power stroke, ADP 
is released and myosin remains bound to actin in rigor (see figure 2 [5]). As long as the 
binding sites on actin remain exposed the cross bridge cycle will repeat. As the cycle repeats 
the thin myofilaments are pulled towards each other and the sarcomere shortens. This 
shortening causes the whole muscle to contract. Cross bridge cycling ends when calcium 
(Ca2+) ions are actively transported back into the sarcoplasmic reticulum.  
The generation of force is dependent on many factors, the muscle size, the number of actin–
myosin cross-bridges formed, the force generated by each cross-bridge, the degree of 
activation by the nervous system, its architecture (the angle at which muscle fibres insert into 
the tendon known as pennation angle) and the quality of the interaction between the cellular 
elements. The term “specific force” has been accepted as an indicator of muscle quality and is 
the generated force by a muscle adjusted for its size.  
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1.1.4 Muscle Fibre Organelles  
  
There are other cellular elements in the sarcoplasm of muscle ﬁbres; these include a trans T-
tubule, the sarcoplasmic reticulum, and a mitochondrial network. In order for muscle 
movement and the mechanisms of action talked about previously to occur, energy (ATP) 
needs to be generated to react with the oxygen made available to the muscle fibre (Dahl et al., 
2015). It is the job of the mitochondria, which forms a three-dimensional network throughout 
the cell to generate the energy needed for muscle actions. Mitochondria can be found located 
closer to the sarcolemma, which reduces the diffusion distance for oxygen transport by the 
capillary supply. Another population of mitochondria is located in the inter-myofibrillar 
space. Mitochondria ultrastructure damage has been described in hind-limb skeletal 
endotoxemic rats more than 40 years ago, with frequent distortion of inner and outer 
mitochondrial membranes and the presence of large vacuole areas (Schumer et al., 1971). It is 
known that various stimuli as well as various neuromuscular pathologies can induce 
significant changes in the structure and function of the mitochondria. Several biophysical 
mechanisms may contribute to the mitochondrial dysfunction among which are disruption of 
mitochondrial membrane integrity, modification of protein side-groups, increased 
degradation or reduced synthesis of the pathway components and desegregation of the 
multiprotein complexes.  
 
1.1.5 Muscle Tissue Heterogeneity 
1.1.5.1 Muscle Fibre Types  
 
The human body is required to undertake various activities with different metabolic and 
mechanical demands, thus the human body has different muscles with differing 
predominance of the various fibre types, classified according to their myosin heavy chain 
(MyHC) composition. The most frequently used classification for adult human limb muscles 
includes three fibre types: type I (slow, oxidative, fatigue-resistant), IIa (fast, oxidative, 
intermediate metabolic properties) and IIx (fastest, glycolytic, fatigable) MyHCs. Humans 
also express, under various conditions and in specific muscles, other types of myosin such as 
embryonic, neonatal, and extra ocular (Schiaffino and Reggiani, 2011). Similarly in rats and 
mice there are four MyHC isoforms that are expressed; type I, IIa, IIx and IIb. Studies using 
isolated muscle fibres have demonstrated an association between force-generating capacity, 
velocity of shortening and MyHC isoform composition (Geiger et al., 2000; Geiger et al., 
1999; Larsson and Moss, 1993; Sieck and Prakash, 1997). These characteristics are very 
plastic and can easily be modified in response to changes in workload, activity or 
pathological conditions. For example, prolonged periods of skeletal muscle inactivity such as 
intensive care unit (ICU) stay or ageing, have been seen to alter MyHC isoform composition 
and force production of single muscle fibres (Gea et al., 2000; Klitgaard et al., 1990; Llano-
Diez et al., 2012; Ochala et al., 2011a).  
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1.1.5.2 Limb versus Respiratory  
 
The diaphragm is the most important inspiratory muscle in mammals and is essential for 
normal ventilation (Poole et al., 1997). Muscle fibres in the diaphragm are classified in the 
same way as in the limb muscle, as either type I or type II MyHC. However the activity of the 
muscles somewhat differ from one another. During normal conditions, the continuous 
rhythmic activation of the diaphragm makes it among one of the most active muscles in the 
body and thus is different to the peripheral muscles. The specific type of loading which the 
diaphragm endures is quite different from that of the postural and locomotor muscles. The 
diaphragm is non-weight bearing and thus in contrast to limb muscles is not exposed to 
gravitational effects.  
 
1.1.6 Skeletal Muscle Plasticity 
 
Skeletal muscle function plays an important role in daily life, but it can also be affected in 
several ways that can impede on our daily lives; in one such case muscle disease. The causes 
of muscle disease are heterogeneous, from alteration in nerves, mitochondria, sarcoplasmic 
reticulum, to nuclei and other intracellular components. Specifically here I address the ICU 
and the associated intensive care unit acquired muscle weakness (ICU-AW), critical illness 
myopathy (CIM). 
 
1.2 THE INTENSIVE CARE UNIT 
 
1.2.1 Intensive care unit-acquired weakness and critical illness myopathy 
 
Perhaps one of the most debilitating environments for muscle is that of the critically ill 
patient in the ICU, with the loss of lean body mass and eventual loss of muscle function being 
key features. There are numerous confounding factors influencing the body and more 
specifically the skeletal muscle. As such, muscle wasting can be triggered by multiple 
conditions, including disuse, denervation, sepsis, fasting, cancer, cardiac failure, renal 
dysfunction and multiple organ failure. It is the exposure to multiple stressors such as fluid 
and electrolyte changes, catabolic stresses, nutritional deficiencies and medications that can 
act in combination to produce damage to the motor unit. Muscle biopsies taken from ICU 
patients with multiple organ failure show a range of histological changes, including severe 
muscle fibre atrophy, degeneration and necrosis (Puthucheary et al., 2013).  
At the cellular level, a reduction in myofibre size reflects an imbalance between proteolysis 
and protein synthesis. This is regulated by complex changes in signalling pathways and gene 
products that are involved in the regulation of protein breakdown (discussed later). The loss 
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of muscle mass and a reduction in force generating capacity in an ICU patient can be termed 
Intensive care unit-acquired weakness (ICU-AW). Whereas ICU-AW is usually accompanied 
by muscle wasting, muscle wasting does not necessarily lead to neuromuscular dysfunction, 
since overall muscle strength depends both on total muscle mass and force generating 
capacity (force per cross-sectional area), which is affected in ICU-AW but not necessarily in 
muscle wasting syndromes (Callahan and Supinski, 2009). As mentioned before, muscle 
force capacity may remain stable in muscle wasting syndromes. 
ICU-AW is a severe complication in critically ill patients that has been increasingly 
recognised over the last two decades. By definition ICU-AW is caused by distinct 
neuromuscular disorders, namely critical illness polyneuropathy (CIP) and critical illness 
myopathy (CIM) (Latronico and Bolton, 2011; Visser, 2006). These conditions are the 
primary cause of muscle weakness and paralysis during and following admission to the ICU, 
irrespective of the underlying conditions. In my thesis the focus lies with CIM, being the 
most frequent neuromuscular disorder underlying muscle weakness in ICU patients (Lacomis 
et al., 2000). Initially, CIM was thought to be a rare event in the ICU; we now know that 
neuromuscular dysfunction is found in up to 30% of the general ICU population and in 70%–
80% of certain sub-groups (Lacomis et al., 2000), thus it is becoming a major problem. Its 
prevalence influences patient prognosis but also bears threats for secondary complications 
(infection, embolism), prolongs ICU treatment and rehabilitation and greatly raises the costs 
of intensive care medicine worldwide.  
MacFarlane and Rosenthal were the first to describe CIM, (MacFarlane and Rosenthal, 
1977), with it being characterised by a reduced muscle membrane excitability, loss of force 
production and a preferential loss of the molecular motor protein myosin (Larsson et al., 
2000; MacFarlane and Rosenthal, 1977). The exact causes of CIM are unknown and are thus 
an area of ongoing research. Immobilisation, prolonged mechanical ventilation, use of 
neuromuscular blocking agents, multi-organ failure and sepsis have all been postulated as 
possible triggering factors. Immobilising patients by deep sedation and mechanically 
ventilating them during the acute phase of critical illness is suggested to contribute to the 
muscle weakness, however by itself, the immobilisation (pure bed rest) may be insufficient to 
explain the degree of muscle atrophy and weakness observed in acutely ill patients (de 
Jonghe et al., 2009). We have previously shown that it is the complete loss of mechanical 
stimuli, both external (loss of weight bearing) and internal mechanical load (activation of 
contractile proteins) i.e. mechanical silencing of skeletal muscle that is a dominating factor 
triggering the preferential myosin loss, atrophy and loss of force-generating capacity (specific 
force - SF) in fast- and slow-twitch skeletal muscles in a rat model (Larsson et al., 2000; 
Ochala et al., 2011a) which results in this severe and specific muscle wasting condition, CIM. 
This complete mechanical silencing is unique to ICU patients and different from other 
unloading conditions, i.e. bed rest, hind limb suspension, microgravity (Zhang et al., 2007).  
This weakness can undoubtedly complicate the course of a significant number of ICU 
patients. The associated muscle weakness with CIM can affect both the limb and the 
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respiratory musculature and more rarely both facial and extra-ocular muscles (Akkad et al., 
2014). This can reduce the chances of patient survival or of a full recovery, by complicating 
the weaning process from the ventilator; increasing the length of stay in the ICU and delay 
mobilisation and physical rehabilitation of the patient (Ali et al., 2008; Hiesmayr, 2012). 
Understanding the mechanisms underlying CIM is an on-going and complex web. 
 
1.2.2 Mechanical ventilation and Ventilator Induced Diaphragm Dysfunction  
 
Diaphragm function preservation is of critical importance to overall health in the process of 
ageing and in the critically ill. Mechanical ventilation (MV) is a life-saving intervention used 
in approximately 40% of adult ICU patients with respiratory failure for a median duration of 
5 to 7 days. MV, although lifesaving is also associated with a variety of major complications, 
these include pneumonia, cardiovascular compromise, barotrauma, ventilator-induced lung 
injury (VILI) and an increased risk of morbidity and mortality (Esteban et al., 2000; 
Winkelman, 2013; Wunsch et al., 2010). In the late 1970s, ventilator-induced lung injury 
became recognised as a serious complication of mechanical ventilation (Dreyfuss and 
Saumon, 1998). Our understanding of prolonged MV resulting in diaphragmatic dysfunction 
has increased dramatically. The first study to document the impact of MV on rodent 
diaphragm atrophy and contractile function was in 1994, (Le Bourdelles et al., 1994) it 
revealed that 48 hours of controlled mechanical ventilation (CMV) (i.e., full ventilator 
support of breathing) resulted in significant loss of diaphragm mass and a large reduction in 
maximal diaphragmatic specific force production. This detrimental impact of prolonged 
rest/inactivity on the diaphragm, induced by CMV triggering diaphragm dysfunction has been 
termed ventilator-induced diaphragm dysfunction (VIDD) (Vassilakopoulos and Petrof, 
2004). VIDD is defined as a loss of diaphragmatic force-generating capacity that is 
specifically related to the use of mechanical ventilation (Vassilakopoulos and Petrof, 2004) 
and is supplementary to an increased difficulty in weaning patients from the respirator. Both 
animal and human experiments consistently demonstrate that prolonged MV promotes 
diaphragmatic atrophy resulting in a reduction in diaphragm mass, and furthermore 
diaphragmatic weakness (Corpeno et al., 2014; Haitsma, 2011; Levine et al., 2008; Powers et 
al., 2002). The mechanisms causing VIDD are considered intrinsic to diaphragm muscle 
fibres, rather than related to alterations in the lungs, thorax/abdominal compliance or neural 
input (Jaber et al., 2011; Powers et al., 2013; Radell et al., 2002). Since diaphragmatic 
dysfunction (in part) determines the ability of patients to be successfully weaned from the 
ventilator, it is therefore of critical importance to understand the effect of mechanical 
ventilation on diaphragm function.  
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1.2.3 Nutrition in the Intensive Care Unit 
 
Nutritional support is an integral component of our general health maintenance, conservation 
and restoration and thus if combined with the ICU and the critically ill population of patients, 
it is perhaps of even greater importance. As such the administration of artificial nutrition has 
been advocated to attenuate muscle loss, however the success of which remains to be 
demonstrated (Casaer et al., 2013; Streat et al., 1987). 
1.2.3.1 Nutritional guidelines 
  
Nutritional support is generally considered an essential component in the management of 
critically ill patients, however current guidelines regarding nutritional support in the ICU are 
mainly based on physiological statements (Singer et al., 2009). Furthermore malnutrition is 
commonly observed among patients admitted to the ICU. Large audits including thousands of 
patients worldwide have shown that in daily practice calorie and protein administration are 
well below current recommendations, varying between 1200 and 1450kcal/day and 0.5 – 
0.8g/kg/day of protein (Alberda et al., 2009). As such this problem can be exacerbated by a 
prolonged hospital stay resulting in a reduced energy and protein intake, increased energy 
expenditure and protein catabolism (Kim et al., 2010; O'Leary-Kelley et al., 2005; Schetz et 
al., 2013b). Perhaps the key question to ask is whether artificial nutrition administered during 
critical illness can prevent, improve or correct this nutritional deficit and thereby also the 
associated adverse outcomes, or if in fact it can worsen the outcome. This impact has thus far 
not been adequately addressed. The more specific question that is addressed here is the role 
that the nutritional deficit may play in specifically triggering CIM. 
Administration of artificial nutrition without doubt, improves energy and protein intake, 
however on the contrary the un-physiological intervention of artificial nutrition may evoke 
complications and side effects. As such aggressive nutritional support in critically ill patients, 
instead of preventing muscle loss or reducing proteolysis and gluconeogenesis, merely results 
in fat gain (Hart et al., 2002; Streat et al., 1987). Furthermore it has been seen in rabbits that 
there is a direct link between nutrition and organ failure. Critically ill rabbits showed that 
early parenteral nutritional (PN) feeding, suppressed the ubiquitin–proteasome pathway, 
thereby contributing to the preservation of muscle mass, but also evoked a phenotype of 
autophagy deficiency in liver and skeletal muscle, suggesting that the maintenance of muscle 
mass might come at the price of accumulation of toxic protein aggregates, thus compromising 
function (Derde et al., 2012). Thus, whether artificial nutritional feeding prevents accelerated 
muscle catabolism in immobilised critically ill patients with systemic inflammation and to 
what extent it can prevent/attenuate muscle wasting/weakness or accelerate recovery 
specifically in CIM patients, remains as yet unclear. 
The overall aim of nutritional care in the ICU is to minimise ‘acute disease-related 
malnutrition’; adequate nutritional care takes into consideration the acute disease itself, the 
interactions of chronic diseases, pharmacological interventions and organ dysfunction 
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(Hiesmayr, 2012). However it is debated as to the type of feeding that is most appropriate for 
ICU patients, enteral or parenteral (Casaer et al., 2011a; Hermans et al., 2013). The existing 
guidelines advocate early enteral nutrition, with the optimal timing for the addition of 
parenteral nutrition to insufficient enteral feeding being the subject of transatlantic 
controversy. Several guidelines, observational studies and meta-analysis support an early start 
of artificial nutrition within 24-48 hours of ICU of admission, of which the severely ill 
patients appear to benefit most. However there are some discrepancies that exist between 
different guidelines. Both the European Society for Clinical Nutrition and Metabolism 
(ESPN) (Singer et al., 2009) and American Society for Parenteral and Enteral Nutrition 
(ASPEN) (McClave et al., 2009) guidelines support an early start of feeding. However a large 
interventional study has been carried out comparing these two methods and have found there 
to be no benefit of early parenteral nutrition with regards to mortality and a clear 
disadvantage in resource use due to the duration of artificial ventilation and length of stay in 
the ICU (Casaer et al., 2011a). Furthermore Herman’s et al (2011) carried out a sub analysis 
to the Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically Ill Patients 
(EPaNIC) trial and found that tolerating a substantial macronutrient deficit early during 
critical illness did not affect muscle wasting, but allowed more efficient activation of 
autophagic quality control of myofibres and reduced weakness and in fact that nutritional 
interventions may have an adverse effect on muscle whilst suppressing autophagy (Hermans 
et al., 2013). Summarizing the clinical trials cited above, there is no evidence for increased 
energy/protein provision during ICU week 1 in protecting muscle mass, muscle force or long-
term physical function. A potential explanation for the pattern of on-going muscle wasting 
despite increased energy and protein intake may be found in its pathogenesis (Casaer et al., 
2013; Owais et al., 2014). The mechanisms underlying muscle atrophy and weakness in 
critical illness are extremely complex (Llano-Diez et al., 2011; Sandri, 2008), and thus 
expecting the atrophy and weakness to be reversible by simply providing calories and protein 
is perhaps an oversimplification of the situation.  
 
1.2.4 Ageing and the Intensive Care Unit 
 
The general population is an ageing one, with life expectancy and the number of men and 
women in older age groups increasing dramatically in the last century. Ageing and chronic 
disease reduces whole skeletal muscle performance that in turn impacts on the individual’s 
ability to undertake everyday tasks. Furthermore ageing is associated with an increased 
incidence of chronic health conditions as well as an increase in the prevalence of impairment 
and disability. Visual and hearing impairments, cognitive decline, musculoskeletal disorders, 
frailty and sarcopenia all reduce activity and restrict participation in personal, work 
associated and social activities. Thus as a consequence it has been estimated that the number 
of older people requiring long-term care due to loss of functional independence will 
quadruple by 2050, undoubtedly having a financial impact on society (WHO, 2015). Our 
physical functional capacity is strongly dependent upon skeletal muscle power output, which 
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is calculated as the product of the force generating capacity and contractile velocity of the 
motor unit (Reid and Fielding, 2012). As such with ageing and disease this has been seen to 
decrease.  
One of the most distinctive features of ageing is the presence of muscle weakness and 
atrophy; atrophy is defined as a decrease in size due to a loss of organelles, cytoplasm, and/or 
protein. This specific loss of lean body mass associated with ageing was termed “sarcopenia” 
by Rosenberg (Rosenberg, 1989, 1997). Cross sectional studies of men and women have 
shown significant reductions in muscle mass, strength and alterations in body composition 
with advancing age (Frontera et al., 1991; Jubrias et al., 1997). Indeed, ageing is associated 
with a constant decrease in strength of approximately 1-3% per year resulting in qualitative 
and quantitative changes at the single muscle fibre level. Furthermore an ageing related 
decline in the specific force of single muscle fibres is observed (Frontera et al., 2000; Larsson 
et al., 1997). A significant portion of the age-related decrease in muscle force production is 
undoubtedly caused by the concomitant reduction of muscle mass (atrophy), however it 
cannot solely be attributed to this. Alterations in the muscles intrinsic functionality, such as 
reduced force generation and/or contractile speed per muscle size (i.e., muscle quality) may 
also play a role (Raj et al., 2010). The molecular mechanisms underlying these changes 
remain unclear and as such many molecular mechanisms have been proposed to explain such 
dysfunction, including a reduction in myosin protein content. The latter may be related to 
gene transcription with reductions in translation and protein synthesis, leading to a lower 
myosin concentration per unit of muscle cell area. In addition, posttranslational modifications 
of myosin via mechanisms such as oxidation and glycosylation may result in myofilament 
dysfunction and reduce the number of actin-myosin cross-bridges in the strong bound state 
and therefore limit the force and power generation (Lowe et al., 2002; Ramamurthy et al., 
2001). 
Age can also play an important factor in influencing the impact of prolonged MV on 
diaphragmatic function. In fact the negative effects of MV could be compounded further by 
the age-related decrease in diaphragmatic contractile performance. In general, compared with 
young adult animals, ageing results in a reduction in diaphragmatic maximal specific tension 
(Criswell et al., 1997). The collective effect of both ageing and MV-induced diaphragmatic 
contractile dysfunction could mean that patient age is a predictor of difficulties in patient 
weaning. Age-related muscle changes are very complex and involve multiple features and 
mechanisms influenced both by intrinsic and extrinsic environmental conditions. These 
changes to muscle are different to those associated with injuries, chronic diseases and 
immobilisation, so the therapeutic approach must be tailored to the individual case 
considering the changes at the muscle cell level.  
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1.3 MOLECULAR MECHANISMS CONTROLLING MUSCLE MASS AND 
CONTRACTILE DYSFUNCTION 
 
As we have seen thus far skeletal muscle is a highly plastic component of the human body 
and one that can be affected and manipulated by many factors. Muscle mass, like that of any 
other tissue, depends on protein turnover. It can adapt to different pathophysiological 
conditions via activating pathways that regulate protein turnover. The maintenance of skeletal 
muscle mass is determined by a fine balance between protein synthesis and protein 
degradation. Increased protein synthesis and a simultaneous decreases in protein degradation 
results in muscle gain (hypertrophy), in contrast the loss of muscle mass (muscle atrophy) is 
mainly due to a loss of contractile proteins. Changes in protein synthesis result in part from 
modulations of the mechanisms involved in mRNA translation, which involves the initiation, 
elongation and termination steps, the initiation process appears to be a major regulatory event 
(Nader et al., 2002). Thus the cell’s proteolytic mechanisms must be highly selective and 
tightly regulated, since the accelerated destruction of an essential protein or the failure to 
degrade a short-lived regulatory protein could drastically alter cell function. By understanding 
the hypertrophy and atrophy signalling pathways and identifying the process by which either 
or none are up or down-regulated and/or interact together, could allude to the process by 
which atrophy occurs and is stimulated in ICU patients. The focus for my thesis will be on 
the signalling pathways involved in muscle atrophy. 
 
1.3.1 Atrophy signalling pathways 
 
Muscle atrophy is an active process controlled by specific signalling pathways and 
transcriptional programs. There are three major proteolytic systems contributing to skeletal 
muscle protein loss: the cytosolic calcium-dependent calpain system, the lysosomal proteases 
and the ATP-dependent ubiquitin proteasome system (UPS). The UPS pathway is responsible 
for 80–90% of intracellular protein turnover (Solomon and Goldberg, 1996). This ATP-
dependent process requires sequential interaction among three families of enzymes: ubiquitin 
activating enzymes (E1 proteins), ubiquitin conjugating enzymes (E2 proteins), and ubiquitin 
ligases (E3 proteins). There are several hundred E3’s that have been identified and it is likely 
that each modulates the ubiquitination of a distinct set of substrates. Animal research would 
suggest that in particular two E3s are uniquely expressed in skeletal muscle: muscle atrophy 
F-box (MAFbx/atrogin-1) and muscle RING finger 1 (MuRF1). The functional importance of 
these gene products in atrophy processes was demonstrated by the generation of MAFbx−/− 
and MuRF1−/− mice. Mice lacking either gene showed sparing of muscle mass following 
denervation (Bodine et al., 2001; Gomes et al., 2001). These ubiquitin ligases 
(MAFbx/atrogin-1 and MuRF1) are instrumental to the processes of muscle protein 
degradation observed during muscle atrophy conditions (Glass, 2003), thus this pathway will 
be the focus here. 
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Critical illness and MV have both been seen to attribute to an increased expression of 
MAFbx/atrogin-1 and MuRF1 in both human and rat limb and diaphragm muscle 
(DeRuisseau et al., 2005; Glass, 2005; Hussain et al., 2010; Llano-Diez et al., 2011; 
Nordquist et al., 2007; Norman et al., 2006; Ochala et al., 2011a). Importantly, recent 
findings suggest that MyHC’s are ubiquitinated and degraded by MuRF1, perhaps in part 
explaining myofibril disassembly (Clarke et al., 2007; Cohen et al., 2009). It has been 
established that it is the preferential loss of myosin that can attribute to the loss of force 
specifically in CIM patients (Larsson et al., 2000; Llano-Diez et al., 2012). The inhibition of 
MuRF1 could be a novel mechanism to prevent or reverse muscle wasting associated with 
various pathologies. The levels of MAFbx and MuRF1 have been described to be controlled 
by the insulin-like growth factor, insulin growth factor (IGF)-I/Akt/Forkhead Box O (FoxO) 
pathway in which phosphorylation and activation of Akt leads to phosphorylation and 
retention in the cytoplasm of FoxO transcription factors, thereby decreasing gene expression 
and subsequent protein abundance of MAFbx and MuRF-1 and attenuating muscle 
proteolysis (Glass, 2005). It is established that both protein synthesis and degradation are a 
highly orchestrated processes that are tightly regulated within the cells, requiring an 
interacting complex cascades of events, thus invariably things can go wrong, both in the 
healthy population and in the critically ill.  
 
1.4 POTENTIAL INTERVENTION STRATEGIES TO ALLEVIATE CRITICAL 
ILLNESS MYOPATHY 
 
At present there is no specific treatment for CIM, however there have been different therapies 
which have been suggested to reduce the severity of the myopathy. Recently, early 
mobilisation has been proposed to have a positive effect in slowing the development of CIM 
(Brahmbhatt et al., 2010; Griffiths et al., 1995; Llano-Diez et al., 2012; Martin et al., 2005). 
Furthermore pharmacological interventions have been put forward as possible strategies. The 
chaperone co-inducer BGP-15 [O-(3-piperidino-2-hydroxy-1-propyl) nicotinic amidoxime 
dihydrocholride], a known pharmacological co-inducer of heat shock protein (Hsp) 70, was 
recently shown to have a muscle sparing effect and improve muscle architecture, strength and 
contractile function in severely affected diaphragm muscles in a rodent Duchenne muscular 
dystrophy model (Gehrig et al., 2012). The stress-inducible isoform of Hsp70 (Hsp72) is 
associated with the atrophy of muscle fibres and plays an important role in regulating muscle 
fibre size during conditions of muscle atrophy. The first evidence of Hsp72’s involvement in 
regulating skeletal muscle plasticity was through the use of muscle specific Hsp70 transgenic 
mice (McArdle et al., 2004). Hsp72 has been seen to negatively regulate the FoxO and 
Nuclear Factor қB (NF-қB) pathways, which are activated during numerous conditions of 
muscle atrophy (Hunter and Kandarian, 2004; Sandri et al., 2004; Senf et al., 2010). 
Furthermore it has been seen that Hsp’s play an important protective role of myofibrillar 
proteins specifically during CMV and immobilisation (Aare et al., 2011; Banduseela et al., 
2009). The mechanisms by which critical illness contributes to muscle weakness and atrophy 
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are multifaceted and involve several inter-related processes, which can act synergistically. 
Thus with regards to possible intervention strategies it is perhaps not a simple case of “one 
shoe fits all”, which is important to remember with regards to potential intervention 
strategies. 
 
1.5 A HETEROGENEOUS POPULATION; THE NEED FOR AN ANIMAL MODEL 
 
The critically ill ICU group of patients is a complex cohort and one that has many 
independent and complex confounding factors, such as underlying disease state, different 
modes of mechanical ventilation, medications and newly acquired complications, which can 
also impair skeletal and diaphragmatic muscle function (Laghi and Tobin, 2003). To consider 
all of these factors when trying to study and understand the underlying mechanisms of CIM is 
complex. Given the difficulty of a controlled clinical observation, there is a compelling need 
for an experimental animal model. There are very few experimental models where the long-
term effects of MV and immobilisation of skeletal muscle can be studied in detail. The 
porcine model has been for many years been used to study the effects of sepsis on organ 
function (Offner et al., 1995). This was therefore thought to be an ideal candidate for an 
animal model of CIM, due to the well known similarity in metabolism between humans and 
pigs (Norman et al., 2006). One major benefit to the porcine model is the ability to use the 
same ventilators that are used in ICU patients. However experimental rodent ICU models 
offer a cost-efficient alternative to the porcine model, as well as improved logistical 
advantages. Mouse models allow for efficient genetic engineering, but there is increasing 
evidence that the rat is a better model for studies of muscle disease and ageing (Ibebunjo et 
al., 2013). In addition the ability to carry out long term MV in small rodents poses further 
problems, as the majority of commercially available ventilators are unable to maintain life 
support for longer than a few days, which adds a further confounding factor; time, with ICU-
AW phenotypes taking longer than 24 hours to develop. Furthermore the rat and human 
diaphragm are anatomically alike and contain a similar fibre type composition (Powers et al., 
1997), the rat has become the most commonly used animal model to study MV-induced 
changes in diaphragm fibre size and function. An important issue is dissecting the different 
entities of ICU-AW and their pathophysiological mechanisms. The definition of proper 
animal models that as closely as possible mimic the phenotype of the muscle weakness seen 
in ICU patients is therefore imperative. The model that is used in Lars Larsson lab and is used 
for the work in this thesis is an experimental rat model, developed by Barry Dworkin and co-
workers (Dworkin and Dworkin, 1990, 2004). This model mimics the basic ICU conditions 
of long-term mechanical ventilation, sedation and muscle unloading: i.e. absence of 
mechanical loading related to muscle contraction or weight bearing (mechanical silencing) 
(see figure 3). It allows for the unique possibility to conduct time-resolved analyses with a 
high temporal resolution on the effects of the ICU condition on muscle, muscle specific 
difference as well as in the design and evaluation of specific intervention strategies (Larsson, 
2007). 
  21 
2 AIMS 
 
The overall goal of my PhD project is to investigate the importance of potential contributors 
in the development of muscle fibre dysfunction in response to the ICU condition; CIM and 
evaluate the efficiency of one potential therapeutic intervention.   
 
Paper I 
The aim of this study is to investigate the effects of nutritional status in the pathogenesis of 
CIM. By using a unique experimental animal model mimicking the ICU condition we want to 
determine whether nutritional status is driving the preferential myosin loss, fibre atrophy and 
loss of specific force in skeletal muscle, all of which are key characteristics of CIM. 
 
Paper II 
The main aim of this study is to investigate the effect of ageing on rat diaphragm muscle fibre 
structure and function in response to five days of controlled mechanical ventilation. 
 
Paper III 
In this study we have investigated the impact of a new class of ‘membrane lipid therapy’ 
pharmaceuticals (BGP-15) in restoring the heat shock proteins stress response in the 
diaphragm, induced by controlled mechanical ventilation. By using an experimental rat 
model, allowing time-resolved studies for durations varying between 6h and 10 days we 
specifically focus on the effects on mitochondrial structure and function and regulation of 
muscle contraction at the muscle cell level. 
 
Paper IV 
The main aim of this pilot study was to investigate the impact of BGP-15 on diaphragm 
dysfunction in response to 5 days CMV in young adult vs. old rats using a unique 
experimental rat model. 
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3 MATERIALS AND METHODS 
 
Here I will present the methods that are relevant to my personal work, thus the focus will 
remain on the fibre contractility methods. The other methods used in the individual papers 
can be found in the paper references. 
In all papers the same experimental rat model was used, mimicking the intensive care unit 
setting. The rats were anaesthetized, mechanically ventilated and treated with α-cobra-toxin 
for durations varying from 0 days (control) up to 14 days. Female rats were chosen for ease 
of handling and insertion of the urinary catheter. In no experiments did animals show any 
signs of infections, septicaemia, or systemic inflammation. 
 
3.1 ETHICAL CONSIDERATIONS: PAPER I, II, III AND IV 
Animal experiments were carried out at Uppsala University. The Institutional Animal Care 
and Use Committee at the Pennsylvania State University College of Medicine and the Ethical 
committee at Uppsala University approved all aspects of these studies. 
 
3.2 EXPERIMENTAL RAT MODEL  
 
Paper’s I, II, III, and IV 
The experimental model has previously been described in detail (Dworkin and Dworkin, 
1990, 2004) and modified to optimise studies of skeletal muscle. Briefly; (1) 
Electrocardiogram (ECG) electrodes were implanted subcutaneously. (2) An aortic catheter 
(28-gauge Teflon) was inserted via the left carotid artery to record arterial blood pressure. (3) 
A 0.9 mm Renathane catheter was threaded into the left jugular vein to administer parenteral 
nutrition. (4) Three subcutaneous electroencephalogram (EEG) needle electrodes were placed 
into the skull above the right and left temporal lobes, and a third reference electrode was 
placed on the neck. (5) The rat was placed on a heating pad to maintain body temperature; 
temperature was measured by a vaginal thermistor and servo-regulated at 37°C. (6) A silicone 
cannula was inserted in the urethra to continuously record urine output. Neuromuscular block 
(NMB) was induced on the first day (100µg intravenous (IV). α-cobra-toxin) and maintained 
by continuous IV infusion (250µg/day). Rats are ventilated through a per os coaxial tracheal 
cannula at 72 breaths/minute with an inspiratory and expiratory ratio of 1:2 and a minute 
volume of 180–200ml and gas concentrations of 49.5% O2, 47% N2, and 3% CO2, delivered 
by a precision (volume drift <1%/wk) volumetric respirator (see figure 3). Intermittent 
hyperinflations (6 per hour at 15cm H2O), positive end-expiratory pressure (1.5 cm H2O), and 
expiratory CO2 monitoring is continuous. The rat’s vital signs were continuously monitored 
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24 hours a day. All animals were maintained in protein and fluid balance (see nutritional 
information). 
 
Figure 3. Overview of experimental rat model mimicking the basic ICU condition. 
 
Paper III and IV 
In addition in these experiments we tested the pharmacological drug BGP-15, which was 
administered in the intra-venous solution: 40mg/kg/day BGP-15. 
 
3.3 NUTRITIONAL INFORMATION  
 
Paper I 
The daily metabolic requirement calculations were based on the energy consumption in an 
awake rat (Krinke GJ, 2000). The energy is recommended to be ingested in the form of fats, 
carbohydrates and proteins, broken down as: 20% fat (3g), 75% carbohydrates (8.5g), 5% 
protein (0.6g).  
Nutrition was administered parenterally according to the required caloric nutrition (eucaloric 
(EC)) or low caloric nutrition (low calorie (LC)). (Detailed nutritional information is 
presented in paper I table 1). 
For a 300g rat: -  Low Caloric – 11kcal/day 
Eucaloric – 41kcal/day 
In both instances, the LC and EC caloric groups were given the same intra-arterial solution; 
the intra-venous solution differs depending on experimental group and required caloric 
intake. 
Paper II, III, IV 
All of the rats were fed with the eucaloric intake (41kcal/day/kg bw). 
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3.4 ANIMALS  
In paper I and III the rat strain Sprague Dawley (SD) was used.  
Paper I 
Nine female 300g ± 5g Sprague-Dawley rats were included in this study. A total of four rats 
were euthanized after a period of 0 days (serving as controls (C), no mechanical ventilation). 
Five animals underwent surgery to induce the experimental ICU condition and remained in 
the mimicked ICU setting; anaesthetized, mechanically ventilated and treated with α-cobra 
toxin (post-synaptic neuromuscular blockade) for a 10–14 day period. Two animals were 
administered with the EC nutrition and three with LC nutrition. 
Paper III 
Twenty-four adult 369±58.5g female Sprague Dawley rats were included in this study. The 
rats were divided into one control group (n=4) and 5 experimental groups exposed to CMV, 
NMB and deep sedation for 0.25-1 day (n=5), 1-5 days (n=4), 5- 10 days (n=4), 1-5 days with 
BGP-15 treatment (1-5d+BGP, n=3), and 5-10 days with BGP-15 treatment (5-10d+BGP, 
n=4). 
 
In paper II and IV the focus was on the effect ageing may have, thus the rat strain Fisher 344-
Brown Norway (F344-BN) hybrid was used. The F344-BN hybrid rat is recommended for 
age-related studies by the National Institutes of Aging (NIA) because this hybrid rat lives 
longer and has a lower rate of pathological conditions than inbred rats. The rats were obtained 
from the National Institute of Aging (NIA (Bethesda, MD).  
Paper II 
Diaphragm samples were collected from 11 female F344-BN hybrid rats, 7-8 months (young, 
n=7) and 28-32 months (old, n=4). A total of 13 rats were intended for the study, but two of 
the old animals were not included (one had died spontaneously and the other had developed a 
tumour). The rats were randomly classified into two subgroups, 4 young rats and 2 old rats, at 
time 0 days and 3 young, 2 old rats at time 5 days. Soleus and EDL muscles were collected 
from young (6 months, n = 2), middle-aged (18 months, n = 2) and aged (28 months, n = 2) 
rats.  
Paper IV  
Diaphragm samples were collected from 17 female F344-BN hybrid rats, 7-8 months (young, 
n=10) and 28-32 months (old, n=7). Experiments were terminated at durations 0 days and 5 
days. The rats were randomly classified into three subgroups within young and old. 4 young 
rats and 2 old rats, at time 0 days, 3 young, 2 old rats at time 5 days and 3 young, 3 old rats at 
time 5 days with BGP-15.  
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3.5 PASSIVE MECHANICAL LOADING  
 
Paper I 
The left leg of all experimental groups were activated 12 hours per day, using a mechanical 
lever arm that produced a continuous passive maximal ankle joint flexion-extension of 180° 
at a speed of 13.3 cycles per minute. The sham-operated control animals underwent the same 
interventions as the experimental rats, but were not pharmacologically paralyzed with α-
cobra-toxin. That is, sham operated-controls were anesthetized (isoflurane), spontaneously 
breathing, given intra-arterial and intra-venous solutions and sacrificed within two hours after 
the initial anaesthesia and surgery. 
 
3.6 MUSCLE BIOPSIES AND PERMEABLISATION OF FIBRES  
 
Paper I and II 
The extensor digitorum longus (EDL) and soleus muscles were dissected from the loaded and 
unloaded leg immediately after euthanasia. One half of the soleus and EDL muscles were 
quickly frozen in liquid propane cooled by liquid nitrogen and stored at −180°C for future 
analyses. The other half of the soleus and EDL muscle were dissected into bundles.  
Paper II, III, IV 
The diaphragm muscle was dissected immediately after euthanasia. One half of the mid-
costal diaphragm muscle was frozen in liquid propane cooled by liquid nitrogen and stored at 
-180oC for further analyses. The other half was dissected into bundles. 
Specimens were placed in relaxing solution at 4oC and bundles of approximately 50 fibres 
were dissected free and tied with surgical silk to glass capillary tubes at slightly stretched 
lengths. To permeabilise the membrane of the fibres they were treated with skinning solution 
(relaxing solution containing glycerol; 50:50 v/v) for 24 hours at 4°C, after which they were 
transferred to -20°C. The bundles were detached from the capillary tubes and treated with 
sucrose, (a cryoprotectant for long-term storage), snap frozen in liquid nitrogen-chilled 
propane and stored at -180°C.   
 
3.7 SINGLE MUSCLE FIBRE EXPERIMENTAL PROCEDURE AND SPECIFIC 
FORCE MEASUREMENTS  
 
Paper’s I, II, III, and IV 
On the day of experiment, bundles were de-sucrosed; transferred to a 2.0M sucrose solution 
for 30 minutes and subsequently incubated in solutions of decreasing sucrose concentrations 
(1.5–0.5M) and finally kept in a skinning solution at −20°C. A single fibre is removed from 
the muscle bundle and placed between two connectors, at a length of 1 to 2mm long (see 
figure 6A). One connector leads to a force transducer (model 400A, Aurora Scientific), and 
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the other to a lever arm system (model 308B, Aurora Scientific) (see figure 4B). The two 
extremities of the fibre were tightly attached to the connectors.  
 
Figure 4. A) Single soleus fibre attached between two connectors B) Single fibre set- up  
The apparatus was mounted on the stage of an inverted microscope (model IX70; Olympus). 
The sarcomere length was set to 2.65-2.75µm by adjusting the overall segment length and 
controlled during the experiment using a high-speed video analysis system (model 901A 
HVSL, Aurora Scientific). The diameter of the fibre between the connectors was measured 
through the microscope with an image analysis system prior to the mechanical experiments. 
Fibre depth was measured by recording the vertical displacement of the microscope 
nosepiece while focusing on the top and bottom surfaces of the fibre. Cross sectional area 
(CSA) was calculated from the diameter and depth, assuming an elliptical circumference and 
was corrected for the 20% swelling that is known to occur during skinning (Moss, 1979). 
Diameter and depth were measured at three different locations along the length of each fibre 
and the mean was considered a representative of cell dimensions. For the mechanical 
recordings, relaxing and activating solutions (in mM) contained 4 Mg-ATP, 1 free Mg2+, 20 
imidazole, 7 EGTA, 14.5 creatine phosphate and KCl to adjust the ionic strength to 180mM 
and pH to 7.0. The concentrations of free Ca2+ were 9.00M (relaxing solutions) and 4.50M 
(activating solution), expressed as pCa (i.e., -log10 [Ca2+]). Apparent stability constants for 
Ca2+-EGTA are corrected for temperature (15°C) and ionic strength (180mM). At 15°C, 
immediately preceding individual activations, the fibre is immersed for 10–20 seconds in a 
solution with a reduced Ca2+-EGTA buffering capacity. This solution was identical to the 
relax solution except that the EGTA concentration is reduced to 0.5mM, which results in a 
more rapid attainment of steady-state force during subsequent activations. Force was 
measured by slacking the fibre once steady-state isometric force was reached at pCa 4.5. 
Seven different slacks were performed (7-13%) for each fibre and maximum force was 
calculated as the difference between the maximal steady-state isometric force in activating 
solution and the resting force measured in the same segment while in relaxing solution (see 
figure 5). Maximal force production was normalised to CSA (specific force P0/CSA). 
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Figure 5. Original single fibre contraction of rat soleus muscle. Showing residual passive 
force and maximal activate force 
For all the contractile measurements a strict acceptance criteria is applied. A muscle fibre was 
only accepted and included in the analyses if the sarcomere length of a single muscle fibre 
changed by <0.10μm between relaxation and maximum activation and maximal force 
changed by <10% from first to seventh activation. 
 
3.8 MYOSIN HEAVY CHAIN ISOFORM EXPRESSION  
 
Paper’s I, II, IV 
After mechanical recordings each skinned fibre was placed in sample buffer (7.43ml distilled 
water, 2.1ml Glycerol, 1.4ml 10% SDS, 1.75 of 0.5M Trisbuffer pH6.8, 0.32ml bromophenol 
blue, 32.4mg Dithiothreitol, 1ml Leupeptin) in a plastic micro-centrifuge tube and stored at -
180°C for subsequent electrophoretic analysis. MyHC isoform composition of fibres was 
then determined by 6% SDS-PAGE (see figure 6). The acrylamide concentration was 4% 
(wt/vol) in the stacking gel and 6% in the running gel, the gel matrix included 30% glycerol. 
Sample loads were kept small (equivalent to approximately 0.05mm of fibre segment) to 
improve the resolution of the myosin heavy chain bands (types I, IIa, IIx and IIb). 
Electrophoresis was performed at 120 V for 20-22 hours with a Tris–glycine electrode buffer 
(pH 8.3) at 10°C. The gels were silver-stained and subsequently scanned in a soft laser 
densitometer with a high spatial resolution (50μm pixel spacing) and 4096 optical density 
levels. 
 
Figure 6. Myosin heavy chain (MyHC) isoform expression was determined by 6% SDS-
PAGE. Types IIa, IIx, IIb and I. 
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3.9 MYOSIN AND ACTIN RATIOS 
 
Paper I 
The myosin and actin ratio were measured on 12% SDS-PAGE. The total acrylamide 
concentration was 4% (w/v) in the stacking gel, 12% in the running gel, the gel matrix 
included 10% glycerol. Gel electrophoresis was performed at a constant current of 16mA for 
5 h at 15°C. The gels were stained with coomassie blue and subsequently scanned in a soft 
laser densitometer. The volume integration function was used to quantify myosin and actin. 
 
3.10 IMMUNOBLOTTING  
 
Paper IV  
Ten sections from the medial part of the diaphragm were dissolved in SDS buffer (50 
mMTris-HCl, 2% SDS, 0.1% bromophenol blue, 10% glycerol and 2% β mercaptoethanol, 
(pH 8.8), heated for 2 minutes at 95°C. Total protein was quantified using the Pierce 660nm 
Protein Assembly Assay (Thermo Scientific). Equal amounts of protein were separated on 
SDS-polyacrylamide gels (Mini-PROTEAN 3 Cell, Bio-Rad Laboratories) at constant 120 
volts for 90 minutes. Acrylamide concentrations were 4% and 12% (w/v) in stacking and 
running gels, respectively, and the gel matrix included 10% glycerol. Separated proteins were 
transferred to poly (vinylidene difluoride) membranes (Immobilon-P, Millipore). Membranes 
were blocked with 3% non-fat milk powder in Tris-buffered saline containing Tween 20 for 
1 hour and incubated overnight at 4°C with Hsp72 (SMC-100B, StressMarq) and actin (sc-
1616, Santa Cruz Biotechnology Inc.) primary antibodies and then with HRP secondary 
antibodies (anti-mouse, GE Healthcare, and anti-goat, Santa Cruz Biotech). Membranes were 
digitized with ECL 500 Western Blotting Detection Agent Kit (Amersham Biosciences) and 
imaging system (Odyssey, LI-COR Biosciences). Band densities were quantified with Image 
Studio Lite analysis software (LI-COR Biosciences). 
 
3.11 STATISTICAL ANALYSIS  
 
In all paper means and standard error of the mean was calculated according to standard 
procedures. According to statistical criteria the appropriate statistical tests were selected, refer 
to individual papers. 
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4 SUMMARY OF RESULTS 
 
For the purpose of my thesis the focus will remain on the fibre contractility results.  
4.1 PAPER I - THE EFFECT OF NUTRITIONAL STATUS IN THE 
PATHOGENESIS OF CRITICAL ILLNESS MYOPATHY (CIM). 
 
The results from this study (paper I) show that the preferential myosin loss, decline in specific 
force and muscle fibre atrophy did not differ between the low caloric (LC) versus eucaloric 
(EC) group in Sprague Dawley rats in the soleus muscle over a period of 10-14 days.  
 
Body and muscle weight 
In both experimental groups, passive mechanical loading had a sparing effect of muscle 
weight compared to the unloaded leg, independent of nutritional status, in the LC and EC 
groups (see paper I Table 2). In parallel with the decline in body weight, significantly lower 
muscle weights were observed between controls and the two experimental (LC and EC) 
groups. 
 
Muscle fibre size and specific force in muscle fibres expressing fast and slow myosin heavy 
chain (MyHC) isoforms 
Loading 
In both LC and EC groups, passive loading had a significant positive effect on both muscle 
fibre size and force generating capacity (see figure 7) irrespective of muscle fibre MyHC 
isoform expression. Loading appeared to have a stronger effect on both muscle fibre size and 
specific force in the soleus muscle fibres compared with the EDL fibres in accordance with 
the stronger effect of the passive loading on the myosin:actin ratio in the slow-twitch soleus 
than in the fast twitch EDL.  
 
Eucaloric Vs low caloric 
In both the loaded and unloaded soleus and EDL muscle, no significant difference was 
observed between the EC and LC group in the muscle fibre CSA and SF (see figure 7). 
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Figure 7. Average single muscle fibre cross sectional area in the soleus (A) and the EDL (B) 
in the loaded and unloaded limbs in the control (squares), LC (open circles) and EC groups 
(filled circles). Average single muscle fibre specific force in the soleus (C) and the EDL (D) 
in the loaded and unloaded limbs in the control (squares), LC (open circles) and EC groups 
(filled circles). 
 
4.2 PAPER II - AGE RELATED DIFFERENCES IN DIAPHRAGM MUSCLE 
FIBRE RESPONSE TO MID/LONG TERM CONTROLLED MECHANICAL 
VENTILATION. 
 
This study showed an unexpected response of diaphragm fibres to 5 days CMV in F344-BN 
hybrid rats, in both the young (6 months) and old (28-32 months).  
 
Effects of 5 days CMV on diaphragm muscle fibre CSA 
Before any intervention the fibre CSA from the old control animals was significantly larger 
than in young adult controls (see figure 8), furthermore after five days deep sedation, 
neuromuscular blockade (NMB) and CMV this resulted in a compensatory hypertrophy in 
both young and old animals, resulting in a maintained age-related difference in diaphragm 
muscle fibre CSA. 
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Figure 8. Single diaphragm muscle fibre cross-sectional area (CSA) measured at fixed 
sarcomere length in control animals compared with the age-matched animals exposed to 
CMV for 5 days (grey bars: young; white bars: old). Values are means ± SEM. Significance 
level: *p<0.05, ***<0.001. 
 
Effects of 5 days CMV on diaphragm muscle fibre absolute (P0) and specific force 
We see that the absolute force upon maximum Ca2+ activation did not differ significantly 
between young and old animals, however a decline in absolute force was observed in 
response to five day’s CMV irrespective of age (see figure 9A). The age related decline was 
also observed with specific force (see figure 9B), with five days CMV resulting in a 39.8 - 
45.2% decline in young and old respectively, compared to controls.  
 
Figure 9. A) Absolute force B) Specific force of diaphragm fibres measured at fixed 
sarcomere length in control animals compared with the age-matched animals exposed to 
CMV for 5 days (grey bars: young; white bars: old). Values are means ± SEM. Significance 
level: **<0.01, ***<0.001. 
Accordingly we looked into the dominating factor and ascertained that there was an 
interaction between CMV and age (two-way ANOVA p<0.03), furthermore we can suggest 
that there is a dominance of CMV over age from the statistics carried out by the F-test (CMV 
F-value = 66.67; Age F-value = 12.74). During contractile recordings, single diaphragm 
muscle fibres from old animals were frailer than from young, resulting in a larger number of 
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fibres that broke during maximum activation than in the young (0% young control; 15% old 
control; 21% young 5 day-CMV; 35% old 5 day-CMV). The decrease in absolute and 
specific force and a compensatory muscle fibre hypertrophy in response to CMV were 
observed independent of muscle fibre MyHC isoform expression (see paper II table 1 and 2). 
Further, the age-related decline in specific force and increase in CSA was also observed in 
the different fibre types, but statistical difference was not always reached due to the smaller 
number of fibres investigated.  
 
Determining biological age: - Effects of age on CSA and specific force of soleus and EDL 
muscle fibres  
To establish that we looked at biologically aged animals, more specifically aged diaphragm, 
we studied muscle fibre CSA and specific force in female F344-BN hybrid rats in three age 
groups (young, middle-aged and old) to see if muscle fibre size and function differ in the 
same way as in humans and other mammalian species. Single muscle fibres have been 
studied in the fast-twitch EDL and slow-twitch soleus from 6 months, 18 months, and 28 
months old animals. Muscle fibre size did not differ between the 6 and 18-month-old animals, 
but declined in the 28-month group, reaching a statistical significance in the soleus muscle 
(see figure 10A). Specific force was lower in the 28-month group compared with the 6- and 
18-month groups in both the EDL and soleus fibres (see figure 10B). Thus, the changes we 
observed in muscle fibre size and function is in agreement with previous observations when 
comparing young, middle-aged and old individuals.  
 
Figure 10. A) Cross-sectional area B) Specific force (P0 /CSA) measured at fixed sarcomere 
length in single fibres of soleus muscle (grey bars) and of EDL muscle (white bars) from 
animal of different age (individual fibres: young n = 27, middle aged n = 28 and old n = 30). 
Values are means ± SEM. Significance level: *p<0.05; ***<0.001. 
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4.3 PAPER III - THE CHAPERONE CO-INDUCER BGP-15 ALLEVIATES 
MECHANICAL VENTILATION INDUCED DIAPHRAGM MUSCLE 
DYSFUNCTION  
 
Paper III was a continuation from a previous study (Corpeno et al., 2014), to determine the 
effect of the pharmacological intervention BGP-15 on 10 days CMV on the SD rat 
diaphragm. The chaperone co-inducer BGP-15 alleviated the negative effects of CMV on 
diaphragm function by improving diaphragm muscle fibres specific force, and by improving 
mitochondrial respiratory complexes III and IV functions (see paper III). 
 
The effect of CMV and BGP-15 on diaphragm muscle fibre CSA and force generating 
capacity 
The results show that after ten days deep sedation, neuromuscular blockade and CMV a 
significant decrease (~50%) in single diaphragm fibre CSA compared with the controls 
(p<0.001) was observed (see figure 11 A). Furthermore the systemic administration of BGP-
15 during the experimental period did not significantly influence the decline in CSA during 
the ten days CMV. The specific force of the diaphragm fibres declined (p<0.001) 
approximately 70% compared with control values (see figure 13 B). In the rats treated with 
BGP-15, specific force increased (p<0.001) by more than 100% compared with the 10 days 
untreated rats, being approximately 24.2% lower than control values.  For comparison, CSA 
and specific force measurements from a previous study from our group has been added to 
figure 13 (Corpeno et al., 2014), demonstrating good correspondence with present control 
and 10-day untreated animals as well as adding information on the time-course of changes in 
diaphragm muscle fibre CSA and specific force. 
 
 
Figure 11. Single diaphragm fibre CSA measured at fixed sarcomeric length A) and specific 
force B), in control animals (white), animals exposed to CMV for varying durations (black 
bars), animals treated with BGP-15 and exposed to CMV for 10 days (fine striated). Values 
are presented as means + SEM. *p<0.05. **p<0.01 (significant difference compared with 
controls). ***p<0.001 (significant difference compared with controls). 
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4.4 PAPER IV - TARGETING HEAT SHOCK PROTEINS MITIGATES 
VENTILATOR INDUCED DIAPHRAGM MUSCLE DYSFUNCTION IN AN 
AGE-DEPENDENT MANNER 
 
In paper IV we progressed from paper II by exploring the idea that could function be restored 
by use of a pharmacological intervention in our rat model. We looked at the impact of BGP-
15 on diaphragm dysfunction in response to CMV in young adult vs. old F344-BN hybrid 
rats. Our preliminary results show that after 5 days CMV an age dependent significant drop in 
force production is observed, which, by administration of BGP-15, after 5 days CMV 
demonstrates a significant positive effect on diaphragm fibre function in only young rats, in 
conjunction with an increased expression of heat shock protein 72 (Hsp72). 
 
Effects of 5 days CMV with and without BGP-15 on diaphragm single muscle fibre cross 
sectional area (CSA) and diaphragm muscle myosin heavy chain (MyHC) isoform 
composition 
As previously shown in paper II old control individuals were seen to have a larger CSA than 
young, and, after 5 days CMV, deep sedation and NMB a compensatory hypertrophy as seen 
in only the young (see paper II figure 2). With the administration of BGP-15 there was no 
additional effect after 5 days without the drug. 
The IIx MyHC isoform was dominant in all groups and there were no statistically significant 
differences between groups in response to age, CMV or BGP-15 administration (see figure 
12). 
 
 
Figure 12. Myosin heavy chain isoform expression (%) from cross sections in young and old 
rats in control, 5 days CMV and 5 days CMV+BGP-15 groups. (Black: type I, white: type 
IIA, stripe: type IIX, grey: type IIB). Values are % + SEM. 
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Effects of 5 days CMV with and without BGP-15 on diaphragm single muscle fibre specific 
and absolute (P0) force 
The systemic administration of BGP-15 had a significant positive effect on the absolute and 
specific force in the young, but not in the old animals (see figure 13).   
 
Figure 13. Individual rat single diaphragm muscle fibre: A) specific force (Po/CSA) and B) 
absolute force (Po) measured at fixed sarcomere length in control animals compared with age-
matched animals exposed to CMV for 5 days without and with BGP-15. Values are averages 
of individual data from the different animals and the red line indicates the average for each 
group. (Black circles: young; white circles: old; red line: group average). Significance level: 
*p<0.05, **p<0.01, ***p<0.001. 
 
In paper II we reported that the effects of 5 days CMV on specific force, absolute force and 
muscle fibre CSA were independent of the MyHC isoform expressed in the fibre (see paper II 
table 1 and 2). The effects of BGP-15 administration on muscle fibre size, specific and 
absolute force were also independent of MyHC isoform expression (see paper IV table 1).  
 
Effects of 5 days CMV with and without BGP-15 on Hsp72 expression in diaphragm muscle  
In addition to force measurements we looked at the protein expression of Hsp72. Hsp72 
protein levels did not differ between young and old animals in the control group or after 5 
days CMV. However, we see a significant increase in Hsp72 levels in response to 5 days 
CMV+BGP-15 administration, which was solely restricted to the young animals (see figure 
14). 
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Figure 14. Hsp72 protein expression in the diaphragm of control animals (individual rats: 
young n = 4 and old n = 2) compared with the age-matched animals exposed to CMV for 5 
days with (individual rats: young n = 3 and old n = 2) and without BGP-15 (individual rats: 
young n = 3 and old n = 3). (Black bars: young; white bars: old). Values are means + SEM. 
Significance level: *p < 0.05. 
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5 DISCUSSION  
 
In this thesis the overall aim was to investigate the importance of potential contributors in the 
development of muscle fibre dysfunction in response to the intensive care unit condition; 
critical illness myopathy and evaluate the efficiency of one potential therapeutic intervention. 
It is well established that during prolonged critical illness muscle strength and function are 
compromised, which in turn can have a detrimental effect on recovery and more specifically 
in weaning patients from the ventilator (Derde et al., 2010). There are numerous factors and 
mechanisms that can play a part in the process and is thus an area of on-going research and 
the topic of my thesis. In my thesis I look in depth at the specific impact of nutrition (paper I), 
ageing (paper II) and one pharmacological intervention, BGP-15 (papers III and IV). The 
mechanisms behind their methods of action are somewhat of a complicated web and one 
which needs to be better investigated and further understood. 
During the last decade, the seemingly simple task of feeding critically ill patients has become 
exceedingly complex with much controversy, thus the question as to whether nutritional 
therapy in the ICU can prevent or alleviate the associated complications still remains. 
Nutritional factors have been reported to have an impact on skeletal muscle in ICU patients, 
(Derde et al., 2010; Schetz et al., 2013a) suggesting that an insufficient nutrition/caloric 
intake is a possible factor that could be involved in triggering CIM and play a substantial role 
in overall muscle loss and weakness observed in critically ill patients (Beck et al., 2001; 
Friedlander et al., 2005; Griffiths et al., 1997; Plank and Hill, 2000; Schetz et al., 2013b; 
Winkelman, 2013). However it remains unclear and of great debate as to whether artificial 
nutritional support can benefit specifically the outcome of critically ill patients with CIM. 
 
5.1 NUTRITION 
 
In paper I we investigated the impact of nutritional feeding in a rat model mimicking the ICU 
condition, with the aim to study the effects of nutritional status in the pathogenesis of CIM, 
determining whether nutritional status is driving the preferential myosin loss, fibre atrophy 
and loss of specific force in skeletal muscle. The main finding in this study was that 
nutritional feeding of a EC diet did not in fact have a positive effect on the fibre size or force 
generating capacity of the single muscle fibres in the soleus or EDL muscles compared with 
LC feeding. However this study did further confirm the strong impact of mechanical 
silencing associated with the ICU condition in triggering CIM, overriding any potential 
effects of caloric intake in triggering CIM. We saw that irrespective of feeding, the animals 
developed the phenotype considered characteristic of CIM i.e., a preferential myosin loss, 
fibre atrophy and decreased specific force. Thus, we suggest an indication that caloric intake 
is of less importance compared with mechanical silencing in the pathogenesis of CIM in ICU 
patients. Furthermore, neither the myosin:actin nor the positive effect of passive mechanical 
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loading of the hind limb was further effected by feeding, with no additive effect to the loss in 
myosin or in the improvement in muscle fibre size or force generation after a period of 10-14 
days. In accordance with previous data from our group we observed the same reduced 
preferential myosin loss in response to passive mechanical loading, irrespective of caloric 
intake (Renaud et al., 2013).  
 
5.1.1 Current evidence and trials 
 
There is at present an on-going and somewhat controversial debate over the how, what and 
when of feeding ICU patients and even that perhaps the question that should be first 
addressed is whether feeding per se is beneficial. There is a severe lack of consensus at 
present as to what is considered to be the optimal feeding regime in critically ill ICU patients 
(Casaer, 2014). Clinical trials have been undertaken and again the consensus remains unclear. 
The EPaNIC RCT compared early parenteral nutrition supplementing insufficient enteral 
nutrition versus withholding parenteral nutrition during the first ICU-week. It was found that 
early parenteral nutrition provoked more infections and delayed organ function recovery, 
prolonging ICU dependency and hospital stay (Casaer et al., 2011b). Furthermore late 
parenteral nutritional feeding meant patients performed similar 6 minute walking distances 
and activities of daily living despite a shorter hospital stay. Moreover the early parenteral 
nutrition could not prevent the important loss of femoral muscle volume observed in a 
subgroup of 15 neurosurgical patients (Casaer et al., 2013). Despite the provision of 
important amounts of early intravenous energy, protein and insulin, early parenteral nutrition 
was unable to attenuate catabolism, stimulate muscle protein synthesis or prevent the loss of 
myofibre size (Casaer et al., 2011a; Casaer et al., 2013). In summary the clinical data from 
clinical trials, (EDEN, EPaNIC, The Australian Early-PN trial), suggests that there is no 
evidence for an increased energy/protein provision during the first week in the ICU. 
Furthermore, Streat and co-workers found that although malnutrition in the critically ill is a 
recognised predictor of a poor patient outcome, nutritional support in the ICU has proved 
powerless in preventing a loss of lean body tissue (Streat et al., 1987). There is little evidence 
to suggest that muscle mass, muscle force or long-term physical function is protected (Casaer, 
2014, 2015). A potential explanation for the pattern of on-going muscle wasting despite 
increased energy and protein intake (Casaer et al., 2013) may be found in its pathogenesis.  
 
5.1.2 Explanation, ideas and mechanisms of why it may not work 
 
An increased energy/protein administration within the first ICU week does not seem to 
prevent muscle wasting, of which there may be several mechanisms that might underlie this 
anabolic resistance. The precise mechanisms of action by which this phenomenon occurs can 
be alluded to but it is still an on-going area of research. Anabolic resistance, accumulation of 
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intracellular damage, lipogenesis, infectious complications, water accumulation and 
suppression of autophagy might help to explain these findings (Casaer et al., 2013). 
In animal experiments, the driving force behind up-regulated muscle catabolism in critical 
illness has been shown to be linked to multiple processes, non-less so than immobilisation 
and mechanical silencing. In previous experimental and clinical data from our group (Llano-
Diez et al., 2012; Ochala et al., 2011a; Renaud et al., 2013), we have shown that removal of 
both weight bearing and activation of contractile proteins, i.e., ‘mechanical silencing’ of 
skeletal muscle is a dominating factor triggering the specific myopathy (CIM) associated with 
the ICU condition. Furthermore, the loss of muscle mass and function can be attenuated by 
early mechanical loading (Llano-Diez et al., 2012; Renaud et al., 2013) supporting early 
physical therapy in immobilised ICU patients (Bailey et al., 2007). The results from this study 
demonstrate that the loading effect was similar in the LC and EC groups, supporting the 
strong effect of mechanical silencing in the development of CIM and being of greater 
importance compared with caloric intake. In addition to immobilisation, other frequently 
encountered factors such as systemic inflammation in critically ill patients compound this 
loss in muscle mass and function (De Jonghe et al., 2002). It is perhaps becoming clearer now 
that it is the dose of nutrient administration that may be more important than the route, with 
regard to autophagy and eventually in the modulation of clinical outcomes (Casaer and Van 
den Berghe, 2014; Derde et al., 2012; Harvey et al., 2014; Singer et al., 2011). Furthermore 
perhaps what is required within this cohort is a follow up study on the impact of nutritional 
therapy on a long-term patient-centred outcome, particularly on interventions beyond the 
acute phase of critical illness (first week). 
The clinical relevance of nutritional feeding is paramount and should be researched and 
understood further in combination with the premise of early mobilisation.  
 
5.2 AGEING 
 
Mechanical ventilation although being a supportive therapy used in the ICU, comes with 
major complications, compounded further in an aged patient. An increasing proportion of the 
critically ill population are elderly, frail, sarcopaenic patients who start from a compromised 
position with a lower muscle mass and are therefore at a high risk of developing further 
muscle wasting during critical illness. Thus, the main aim of paper II was to investigate the 
effect of ageing on rat diaphragm muscle fibre structure and function in response to five days 
of CMV. An aside to this aim was to better determine the biological age of the animals and 
ascertain whether any differences were present between muscles. 
In paper II, this study showed a significant age related decline in diaphragm muscle fibre 
specific force, with the further addition of the experimental condition of deep sedation, 
neuromuscular blockade and mechanical ventilation, this resulted in an added dramatic 
decline in specific force in both young and old animals after 5 days (paper II and IV). We 
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have previously observed the same decrease in diaphragm and limb specific force in a 
different rat strain (SD) (paper III) and using young rats over a period of 6 hours to 14 days 
(Corpeno et al., 2014) and in a pig model over 5 days (Ochala et al., 2011b). The altered 
diaphragm muscle fibre function in response to mechanical ventilation is suggested to have a 
strong negative clinical effect on the weaning process in ventilated ICU patients. It is 
established that the weaning of elderly patients from the ventilator after a period of time in 
the ICU becomes increasingly problematic with age (Epstein et al., 2002). However in our 
study this negative effect on fibre function was observed in both young and old animals and 
therefore in this instance cannot help to explain the more difficult weaning process in old age. 
However, it is important to mention that in addition to the impaired muscle force generating 
capacity in response to the CMV, we observed that with age the individual muscle fibres 
were frailer and that more fibres broke upon activation, i.e., an additional factor that may 
contribute to the age-related problems in weaning old patients from the ventilator. 
Furthermore we observed an unexpected increased CSA in both young and old animals, 
thought to demonstrate an ineffective compensatory diaphragm muscle fibre hypertrophy in 
response to the 5 days CMV. This was in contrast to our previous data seen in the SD rat and 
pig model (Corpeno et al., 2014; Ochala et al., 2011b) where CSA was maintained for the 
period up to 4 days CMV and then a progressive decline in CSA pursued. This data although 
not as expected and contrary to our previous findings, gives us yet a further insight into this 
complex cohort.  
As a secondary methodological aim to this study we wanted to ascertain that the muscle we 
were using from old female F344-BN hybrid rats were in fact considered “old” rats. 
According to the National Institute of Ageing (NIA) 28–36 month old F344-BN hybrid rats 
correspond roughly to humans in their eighth decade of life. Thus, in an attempt to determine 
the biological age of these rats, we investigated characteristics typical of old age, i.e., muscle 
fibre atrophy and reduction in specific force in the soleus and EDL muscle. We looked at 
three different age groups, representing young (6 months), middle-aged (18 months) and old 
(28 months). A significant age-related decline in muscle fibre size and specific force was 
observed in the 28-month F344-BN hybrid female rats, justifying this age as representing 
biologically old in our studies on the diaphragm. 
Understanding the mechanisms and the aetiology behind this phenomenon is no mean feat 
and one that is the focus of many researchers. The most complicating factor is the cohort 
themselves, with critically ill patients having a whole multitude of confounding factors, 
further identifying the need for a more “clean” animal model. 
In critically ill MV patients the loss of muscle force generating capacity has been established 
and seen to be exacerbated further with age. However the cause of the decrease and the 
underlying mechanisms have only been alluded to in this context and are likely to be 
multifactorial. It is postulated that it may involve the excitation-contraction coupling 
apparatus (Howell et al., 1997; Zhan and Sieck, 1992) with or without the contractile 
machinery; a reduced myofibril protein (Geiger et al., 2001) or possible structural changes 
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may have a detrimental effect on the contractile machinery. Structural abnormalities of 
different subcellular components of diaphragmatic fibres have been observed after 48 hours 
of CMV (Sassoon et al., 2002). The abnormalities include disrupted myofibrils, abnormal 
swelling of mitochondria, lipid droplets, and vacuoles (Corpeno et al., 2014; Picard et al., 
2012; Sassoon et al., 2002). In a previous study carried out in our group using a different rat 
strain (SD) there was an observed early loss of subsarcolemmal neuronal nitric oxide 
synthase activity, onset of oxidative stress, intracellular lipid accumulation and post-
translational protein modifications, which strongly argue for significant qualitative changes in 
contractile proteins causing the severely impaired residual function in diaphragm fibres after 
long-term mechanical ventilation (Corpeno et al., 2014). The mechanisms for the damage are 
unclear but may involve activation of ubiquitin- proteasome proteolysis, calpain proteolysis, 
and oxidative stress (Corpeno et al., 2014; Mitch and Goldberg, 1996; Sandri, 2013; Shanely 
et al., 2002). It has become clearer that specific ubiquitin ligases play a prominent role 
(Sandri, 2008) with the ubiquitin proteasome system being seen to demonstrate the 
degradation of the myosin heavy chain (a major contractile protein). Clarke et al. identified 
the myosin heavy chain as a MuRF-1 partner protein (Clarke et al., 2007). It has further been 
established that FoxO factors are required for the transcriptional regulation of the ubiquitin 
ligases atrogin-1, also called muscle atrophy F-box (MAFbx) and muscle ring finger 1 
(MuRF1), leading to the ubiquitination of myosin and other muscle proteins and their 
degradation via the proteasome (Schiaffino and Mammucari, 2011). 
The surprising increase in CSA is suggested to be an ineffective compensatory hypertrophy. 
Although different to our previous results (paper I and III), in this instance we are using a 
different rat strain, F344-BN hybrid, the preferred strain for ageing studies. We can suggest 
that there are clear differences in rat strains and in the diaphragms response to CMV (paper II 
and IV). We saw the same hypertrophic response in paper IV using the same rat strain. 
The premise that inactivity induces muscle fibre atrophy is widely accepted and has 
essentially become physiological dogma in the literature. However there is suggestion that 
hypertrophy is evident in the diaphragm (Sieck and Mantilla, 2013). Hypertrophic diaphragm 
muscle fibres in response to 5 days CMV has previously been reported in a porcine ICU 
model and further associated with a decline in in vivo diaphragm muscle function (Radell et 
al., 2002). Furthermore in an animal model using male F344-BN rats an age-related increase 
in diaphragm fibre size was reported (van Lunteren et al., 1995). It has been seen that there is 
an increase in the muscular water content, which would explain the decrease in muscle 
protein concentration and the increase in CSA, which is consistent with the increased water 
content that occurs in conjunction with muscular injury (Shanely et al., 2002). Moreover a 
study undertaken in cardiac tissue has demonstrated a similar pattern (atrophy and 
hypertrophy) in senescent hearts of F344-BN rats (Wanagat et al., 2002). This can perhaps 
suggest to us and be matched to our similar finding in the diaphragm, being consistent with 
the idea that this pattern occurs in muscles that remain highly activated with ageing. The 
molecular mechanisms underlying the hypertrophy remain unknown, but are speculated to be 
related to age and CMV changes in mechanosensing and mechanotransduction pathways. 
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This is supported by a decrease in muscle stretch and age related activity of FoxO1 and 
FoxO3a. Thus, the age-related increase in muscle stiffness might be responsible for the 
altered response of the Akt and IKK signalling pathways to the mechanical stimuli, which in 
turn affect the FoxO1 and FoxO activities (Pardo et al., 2008). 
 
5.3 PHARMACOLOGICAL INTERVENTION 
 
Diaphragmatic dysfunction has a strong impact on the ability of patients to be successfully 
weaned from the ventilator, it is therefore of critical importance to understand the effect of 
mechanical ventilation on diaphragm function and explore the possible intervention strategies 
which could be implemented. 
In papers III and IV, we investigated the impact of a pharmacological intervention, BGP-15, 
on restoring diaphragm function in response to CMV. In paper III, SD rats were MV for 
durations between 6 hours and 10 days. We specifically focussed on the effects on the 
regulation of muscle contraction at the muscle cell level and on the effect on mitochondrial 
structure and function. In paper IV, a different rat strain was used (F344-BN hybrid) allowing 
us to investigate the impact of BGP-15 on ageing after 5 days CMV. It was hypothesised that 
the chaperone co-inducer BGP-15 would have a positive effect on diaphragm muscle fibre 
function after varying durations of CMV (paper III and IV) and that the positive effects 
would be more pronounced in the old animals due to a possible compromised heat shock 
protein protection in old age (paper IV). In accordance with our hypothesis it was found that 
the chaperone co-inducer BGP-15 reduced the negative effects of 10 days CMV (paper III) 
and 5 days CMV (paper IV) on diaphragm muscle function. However contrary to the original 
hypothesis the effect after 5 days CMV was primarily observed in the young adult and not in 
the old animals (paper IV).  
 
5.3.1 BGP-15 had a positive effect on SD and F344-BN hybrid young rat 
diaphragm force production (paper III and IV) 
 
Ten days BGP-15 administration to SD rats during CMV exposure doubled specific force 
compared with untreated animals and restored the force generating capacity of diaphragm 
fibres to approximately 75% of it is normal capacity. The molecular mechanisms underlying 
this process are unclear and need to be further investigated. The restored function of the 
diaphragm in only the young F344-BN hybrid rats is of significant importance for gaining 
further knowledge into this highly complex cohort and can help to unravel the possible 
underlying mechanisms, more specifically with the ageing process. At present the exact 
mechanisms are unclear but are likely to be related to the effects of BGP-15 on Hsp70. The 
age-related effect of the chaperone co-inducer is consistent with the increased levels of the 
induced form of Hsp70; Hsp72. Since, it has previously been reported that the up-regulation 
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of Hsp72 contributes to the maintenance of muscle fibre integrity and facilitates muscle 
regeneration and recovery. Conversely Hsp72 expression is decreased during muscle 
inactivity and ageing, with evidence supporting the loss of Hsp72 as a key mechanism that 
may drive muscle atrophy, contractile dysfunction and reduced regenerative capacity 
associated with these conditions (Dodd et al., 2009; Singh et al., 2006). 
 
5.3.2 BGP-15 effect on diaphragm CSA (paper III and IV) 
 
BGP-15 administration during 10 days did not restore the fibre size reduction observed in 
response to CMV exposure in the diaphragm of the SD rats. We have previously shown that 
the early activation of the ubiquitin proteasome degradation pathway and followed by later 
activation of calcium-activated and autophagy degradation pathways play important roles in 
muscle atrophy during CMV (Corpeno et al., 2014). Furthermore in contrast to this in F344-
BN hybrid rats a hypertrophy of fibres was observed, as previously seen in paper II (Cacciani 
et al., 2014), however we see in paper IV that BGP-15 had no additive effect to hypertrophy 
over 5 days CMV in either young or old. This further validates a specific species difference 
and supports the manifestation that different mechanisms underlie muscle atrophy and loss of 
specific force in the diaphragm during mechanical ventilation. Furthermore it is established 
that Hsp70 has an intracellular effect on the inhibition of nuclear factor κB (NF-κB) 
activation, which has profound implications for immunity, inflammation, cell survival and 
apoptosis. The inhibitory potential of Hsp70 over apoptosis occurs via many different 
intracellular downstream pathways (e.g. JNK, NF-κB and Akt), which are directly and 
indirectly blocked by Hsp70. Collectively, these mechanisms underlie Hsp70 anti-apoptotic 
effects in cells under stress conditions (Thiago Gomes Heck, 2012). The inhibition of these 
transcriptional pathways may explain the prevention of muscle-fibre atrophy by Hsp70, since 
NF-κB and FoxO are independently sufficient to cause skeletal muscle atrophy (Sandri et al., 
2004). These evidences suggest that Hsp70 inhibits key signalling pathways for muscle 
atrophy and could potentially be an explanation for the hypertrophy demonstrated in response 
to BGP-15. 
 
5.3.3 The mitochondria (paper III) 
 
In paper III we also looked at the impact that BGP-15 treatment had on the mitochondria in 
the diaphragm muscle after exposure to CMV. BGP-15 has been seen to improve 
mitochondrial efficacy and reduce reactive oxygen species (ROS) production (Henstridge et 
al., 2014). We found that the BGP-15 treatment improved the function of two specific 
mitochondrial respiratory complexes, III and IV, however it did not improve the structural 
changes that occurred in response to the CMV. 
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The improved function of complex III and IV can help us to understand further the increased 
force production of the diaphragm. Among BGP-15’s multiple targets, its action as a poly 
ADP ribose polymerase (PARP) inhibitor is of specific interest since PARP inhibition 
reduces mitochondrial ROS production and ROS-related oxidative damages during stress 
(Bowes et al., 1999; Halmosi et al., 2001; Szabados et al., 2000). The strong negative impact 
of post-translational modifications of myosin on the dramatically impaired diaphragm muscle 
fibre function in response to long-term CMV (Corpeno et al., 2014) and the reduction in ROS 
production by BGP-15 resulting in decreased oxidation of contractile proteins is forwarded as 
a critical mechanisms underlying the approximate 75% increase in diaphragm muscle fibre 
force generating capacity. 
 
5.4 STUDY LIMITATIONS 
 
5.4.1 Sample size 
I think it is important to make clear that we are aware of the low number animals per groups. 
However it is also of importance to point out that for our studies of up to 14-day, significant 
time and resources are needed to make these studies possible. However in-spite of this we felt 
that the knowledge that could be gained from the studies would provide vital information to 
the community and enable us to use the data from these studies to design future studies with 
correctly powered groups.  
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6 CONCLUDING REMARKS 
 
Critical illness myopathy is a common and complex manifestation seen in ICU patients and it 
has over the past decade become an increasing problem that will only escalate further. 
Understanding the processes and underlying mechanisms of muscle regulation with respect to 
CIM is an area of great research focus. My thesis has provided some further insight into this 
highly orchestrated process using a rodent model mimicking the ICU environment.  
We have ascertained here (paper I) that the impact of mechanical silencing associated with 
the ICU condition overrides any potential effects of eucaloric feeding in triggering CIM in 
the limb muscle of SD rats. Furthermore, we observed that eucaloric feeding had no greater 
effect on muscle fibre size or force generating capacity over that of passive mechanical 
loading of the limb muscles. We can in this instance suggest that perhaps alternative feeding 
strategies may have a beneficial effect. 
Ageing is a process that we will inevitably all experience and one that requires in-depth 
research and understanding. Combine the complex process of ageing muscle with that of the 
ICU environment and CIM and we confound the task in hand. A major problem in the ICU is 
weaning patients from the ventilator; a problem that is exacerbated in the elderly. Thus, 
having a better understanding of the effect of MV on the young and elderly population can 
help. Using the rat strain F344-BN hybrid we observed an ineffective compensatory 
hypertrophy in the diaphragm in response to 5 days CMV with a concomitant decrease in the 
force generating capacity in both the young and old (paper II and IV). This does not offer us 
an explanation as to why the problem of weaning is more problematic in the old, however we 
did observe in the old an increased number of frail diaphragm muscle ﬁbres in both controls 
and after mechanical ventilation. This can perhaps lead us to believe that there is another 
possible mechanism that may be of signiﬁcant clinical importance. 
With the premise that things can go wrong with the human body, research is ongoing in both 
trying to understand the possible mechanisms and taken one step further in finding possible 
preventative and intervention strategies. As such in the context of my thesis we evaluated a 
pharmacological intervention with the desire to assuage diaphragmatic dysfunction in an ICU 
mimicking model. The drug BGP-15 was found to alleviate the negative effects of CMV on 
diaphragm function by improving muscle fibre specific force and by improving 
mitochondrial respiratory complexes III and IV functions (paper III). In addition we wanted 
to investigate further the age related differences seen in paper II and thus administered young 
and old F344-BN hybrid rats with BGP-15 (paper IV). We observed a further significant age-
specific difference with BGP-15 having a strong positive effect on diaphragm muscle fibre 
function in only the young rats with a matched increase in Hsp72 expression after 5 days 
CMV. Thus it is suggested that the increased Hsp72 expression, induced by BGP-15 is an 
indicator of the inhibition of the atrophy pathway (UPS), that as such attributes to an 
increased CSA and specific force in only the young. 
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This research has made it more apparent the complexity of understanding this field, with 
differences observed between the diaphragms of different rat strains. Muscle heterogeneity is 
an important point to remember with regards to the differences that are elicited between 
muscle types, fibre types, species and age. Force production, fibre size and the time course 
over which changes can occur are all elements which can differ and which are seen to be 
intensified further by the process of ageing. This heterogeneity factor is an aspect that has 
meant that in the literature you can find contradicting and confusing results, thus making it 
difficult to ascertain the exact underlying mechanisms. Therefore it has become clearer that in 
fact a multifactorial process may proceed and is something that needs careful consideration 
when planning future research. 
As I have alluded to previously it is important for us to be aware that the group sizes in these 
experiments are low and thus in this instance a follow up study should be undertaken to 
further investigate the possible highly clinical significance of this research. 
 
7 ONGOING AND FURTURE WORK 
 
To further the knowledge in relation to this work there are ongoing studies to investigate the 
underlying mechanisms of the muscle in the ICU environment, by investigating the potential 
signalling mechanisms involved. Having established that BGP-15 has a positive influence on 
muscle force production after exposure to CMV in the young F344-BN rats with a 
concomitant increase in Hsp72 expression (paper IV) we would like to continue to investigate 
the associated atrophy pathway.  
As it is discussed the inhibitory potential of Hsp70 over apoptosis occurs via many different 
intracellular pathway (e.g. JNK, NF-κB and Akt), which are directly and indirectly blocked 
by Hsp70. This and further evidences suggest that Hsp70 inhibits key signalling pathway for 
muscle atrophy (Thiago Gomes Heck, 2012). Muscle atrophy results primarily from 
accelerated protein degradation and is associated with increased expression of two muscle-
specific ubiquitin ligases (E3s): atrogin-1 and MuRF1 (Sacheck et al., 2004; Sandri et al., 
2004), as such gene expression of MuRF1 and atrogin-1 will be investigated.  
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